Avelumab internalization by human circulating immune cells is mediated by both Fc gamma receptor and PD-L1 binding

Avelumab is an IgG1 anti–programmed death ligand 1 (anti–PD-L1) monoclonal antibody that has been approved as a monotherapy for metastatic Merkel cell carcinoma and advanced urothelial carcinoma, and in combination with axitinib for advanced renal cell carcinoma. Avelumab is cleared faster and has a...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Hulin, D'Urso, Vittorio, Neuteboom, Berend, McKenna, Sean D., Schweickhardt, Rene, Gross, Alec W., Fomekong Nanfack, Yves, Paoletti, Andrea, Carter, Carina, Toleikis, Lars, Fluck, Markus, Scheuenpflug, Juergen, Cai, Ti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409756/
https://www.ncbi.nlm.nih.gov/pubmed/34484871
http://dx.doi.org/10.1080/2162402X.2021.1958590

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409756/
https://www.ncbi.nlm.nih.gov/pubmed/34484871
http://dx.doi.org/10.1080/2162402X.2021.1958590

Ejemplares similares